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AbShCt 
The kinetics and equilibria of S-nitrosothiol-thiol (SNO-SH) exchange reactions were determined using differential optical absorption. At pH 7.4 
and 37’C, k2 values ranged from 0.9 M-i . s- ’ for the reaction between S-nitroso-glutathione (GSNO) and N-acetyl-penicillamine, and up to 
279 M-’ . se1 for the exchange between S-nitroso-penicillamine (penSNO) and GSH. SNO-SH exchange involving GSIWGSNO and cysteine/cySNO 
was relatively rapid, k, approx. 80 M-’ . s-’ with an equilibrium constant slightly in favour of GSNO. GSNO was strongly favoured in equilibrium 
with penSNO, k, 0.0039. In the case of SNG-SH exchange between S-nitroso human serum albumin (albSN0) and GSH or cysteine k2 values were 
3.2 and 9.1 M-i . s-l, respectively. The results show that the initial rate of SNO-SH exchange between physiological albSN0 (7 @I) and venous plasma 
levels of GSH and cysteine is very slow, < l%/min. On the other hand, if a nitrosothiol such as cySN0 were to enter a cell, it would be rapidly converted 
to GSNO (43%/s). 
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1. Introduction 
S-Nitrosothiols (RSNO) can elicit many of the various 
physiological regulatory functions attributed to nitric 
oxide/endothelium-derived relaxing factor, including 
smooth muscle relaxation [l-4], platelet deactivation 
[5,6], immunosupression [7] and neurotransmission [8]. 
RSNO occur in human venous plasma mainly as S-ni- 
troso-albumin (7 PM) [9], and 0.3 ,uM GSNO has been 
measured in human bronchial lavage fluid [lo]. How- 
ever, the significance of endogenous RSNO is unclear. 
They may serve as a storage form of NO, intermediates 
in the excretion of NO as nitrite ion, or as specific phys- 
iological mediators. Regardless of the significance, if 
any, of endogenous RSNO, there appears to be consider- 
able therapeutic potential for exogenous RSNO in areas 
such as the regulation of blood pressure, prevention of 
blood clotting, bronchodilation and smooth muscle re- 
laxation for surgical procedures. Hence, various RSNO 
have been the subject of recent patents. However, these 
low molecular weight compounds are generally thought 
to undergo very rapid [ 141 or ‘instantaneous’ [15] SNO- 
SH exchange reactions, which complicates the attribu- 
tion of physiological effects to a specific nitrosothiol [ 161, 
but a kinetic and equilibrium analysis of SNO-SH ex- 
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change involving the important biological thiols, GSH, 
cysteine, serum albumin and thiol drugs, is lacking. We 
have therefore determined the kinetic and equilibrium 
constants of these reactions to assess their potential sig- 
nificance in vivo. 
2. Materials and methods 
2.1. RSNO preparation 
GSH (free acid), cysteine .HCl, penicillamine, N-acetyl-penicilla- 
mine, human serum albumin (crystallised), bathocuproine disul- 
phonate, deferoxamine mesylate and n-butyl nitrite were obtained from 
Sigma-Aldrich (Poole, UK). 
Non-protein S-nitrosothiols were prepared by mixing solutions of 40 
mM thiol containing 10 PM bathocuproine-disulphonate (BCS) and 40 
mM HCl at @-4”C with 118 vol. of 400 mM cold NaNo,. The reaction 
appeared complete within 6 min. 2 vols. of buffer A (100 mM NaCl, 
10 PM BCS, 10 PM deferoxamine mesylate, 30 mM Na-phosphate, pH 
7.40) was then added and the solution kept on ice. 
Human serum albumin was dissolved in buffer A to 150 mg/ml and 
10 mM dithiothreitol and 10 mM EDTA added. After 1 h at 2O”C, 
dithiothreitol and EDTA were removed by passage through Sephadex 
G-25 (Pharmacia-LKB, Milton Keynes, UK) equilibrated in buffer A. 
Albumin concentration was determined from the UV spectrum 
(~r,s = 3.89 x lo4 M-’ . cm-’ [17]). S-Nitrosylation of the albumin thiol 
was then achieved by incubation with a 5-fold molar excess of n-butyl 
nitrite at 37’C until no further increase in AsM was seen (approx. 8 min). 
0.98 mol albSN0 was obtained per mol albumin using .s3% = 870 
M-’ . cm-’ for albSN0. 
mQ-grade water (Rr 18 MG.cm) and tissue culture-grade plastic 
labware were used for all solutions. 
2.2. Quantitation of S-nitrosothiol-thiol exchange 
Absorption spectra of freshly prepared S-nitrosothiols were obtained 
between 300 and 650 mn using a Perkin Elmer Lambda 5 spectro- 
photometer. The absorption peak at 600 mn, characteristic of S-ni- 
troso-penicillamines, was used to monitor SNO-SH exchange of a 
penicillamine/penSNO/SNAP with either GSIWGSNO or cysteine/ 
cySN0 (.ssoo = 10.2 M-i . cm-‘). To cot&-m that SNO-SH exchange 
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occurred, rather than merely decomposition of penSNO/SNAP, the 2.3.2. Method 2. For the slower exchange reactions (those not in- 
reactions were also monitored at 541 nm where there is a concomitant volving peniciJlamine) k, values were also obtained from pseudo-first 
increase due to GSNOkySNO formation. SNO-SH exchange involving order rate constants obtained from the reaction of a lo- to 15- fold 
GSH and cysteine or albSN0 and GSH was analysed using the lower excess of thiol with S-nitrosothiol. This method was also used for 
molar absorptivity of CysNO/albSNO compared to GSNO at 334 mu exchange between albSN0 and GSH which differed in their molar 
(a = 90 M-’ . cm-‘; D.J. Meyer, unpublished observations). absorptivity at 334 mn. 
2.3. Analysis of kinetics and equilibria of RSNO-thiol exchange 
2.3.1. Method I. k2 and k& were determined by reacting equimolar 
amounts of thiol and S-nitrosothiol. S-Nitrosothiol, 0.5-2.5 mM in 
buffer A, was placed in a fresh polystyrene cuvette (Boehringer- 
Mannheim, Lewes, Sussex) at 37’C and AS, m or A, m was moni- 
tored for 2 min to obtain the slow decomposition rate. An equimolar 
amount of thiol was added, mixed and the exchange reaction monitored 
until equilibrium was reached. The thiol and S-nitrosothiol components 
were interchanged and the reaction repeated. Experiments were re- 
peated at least once, and in the case of thiol and S-nitrosothiol of 
penicillamine and GSH the experiments were also repeated at different 
sets of reactant concentrations. The second order rate constant (k,) for 
each reaction was obtained by plotting l@irst RSNO or 6rst tbiol] vs. 
t and the equilibrium constant (Q was calculated, both from the ratio 
of k, values for the forward and reverse reaction and directly from the 
equilibrium attained in each experiment. 
2.3.3. Method 3. albSN0 and cySN0 showed similar molar absorp- 
tivity at 334 ~1. Therefore, to monitor SNGSH exchange, use was 
made of the great sensitivity of cySN0 to copper-dependent decompo- 
sition (D.J. Meyer, unpublished observations). Thus albSN0 in buffer 
A was mixed with an excess of cysteine in the presence of 20pM CuSO, 
(10pM excess over bathocuproine disulphate content of buffer A). The 
first order decay of A3+, was then due to the transfer of nitrosyl- to 
cysteine. 
3. Results and discussion 
An example of SNO-SH exchange involving GSH and 
penSNO using method 1 is shown in Fig. 1. The reaction 
yields an average k2 of 279 f 33 M-’ . s-’ (S.E.M., n = 8), 
Table 1 
Kinetics and equilibria of S-nitrosothiol-thiol exchange reactions 
RSNO [RSNOI WW Thiol [Tnioll WW k, (M-r . s-‘) 
GSNO (A) 
PenSNO (C) 
2.3 
2.3 
2.3 
0.7 
0.7 
1.4 
1.4 
1.4 
2.3 
2.3 
2.3 
Pen (B) 
GSH @) 
2.3 1.25 
2.3 0.80 
2.3 1.20 
0.7 316 
0.7 190 
1.4 222 
1.4 215 
1.4 330 
2.3 317 
2.3 460 
2.3 180 
GSNO (A) 
SNAP (C) 
2.3 
2.3 
0.7 
NAP (B) 
GSH (D) 
2.3 0.9 
2.3 1.1 
7.0 1.25” 
CySNO (A) 
SNAP (C) 
2.3 
2.3 
0.7 
NAP 09 
Cysteine (D) 
2.3 1.3 
2.3 3.0 
7.0 3.2” 
GSNO (A) 
WSNO (C) 
0.6 
0.4 
0.6 
0.4 
Cysteine (B) 
GSH (D) 
0.6 83 
4.0 60” 
0.6 102 
4.0 74” 
albSN0 0.2 GSH 3.0 
albSN0 0.2 Cysteine 3.0 
0.0014-0.0043 
0.0039 
0.83 
0.83 
0.77 
0.42 
0.40 
0.38 
0.91 
0.83 
0.83 
3.2 
9.1d 
Equilibrium constants are calculated for the reaction: 
*2 
A+B +C+DwhereK=$=E 
k-2 2 
k, and k-, are second order rate constants and [A], [B], [C] and [D] are the concentrations of reactants and products at equilibrium. 
“k& calculated from the ratio of average second order rate constants. 
“Q derived from individual reaction end-point (method 1, section 2.3.1.). 
‘k2 obtained from pseudo-first order rate constant (method 2, section 2.3.2.). 
dk2 obtained from pseudo-first order rate constant (method 3, section 2.3.3.). 
D. J. Meyer et al. I FEBS Letters 345 (I 994) 177-180 
and an equilibrium which is greatly in favour of GSNO 
(Table 1). No significant difference was observed be- 
tween p- and L-penicillamines (not shown). The reaction 
of GSH or cysteine with SNAP is about 2 orders of 
magnitude slower, the equilibria also favouring GSNO 
or cySN0, respectively, but to a lesser extent than with 
penicillamine (Table 1). Penicillamine is used clinically 
as a copper-chelating drug to treat Wilson’s disease [181. 
The relatively unfavoured formation of penSNO may 
contribute to its lack of side effects. 
SNO-SH exchange involving cysteine and GSH 
yielded k2 values of about 80 M-’ . s-l in each direction. 
This means that at the low concentrations of cysteine and 
GSH in plasma, SNO-SH exchange is calculated to be 
very slow. For example with 0.3 PM GSNO (as found 
in bronchiolar lavage fluid [lo]), the initial rate of ex- 
change with a human venous plasma level of cysteine of 
9.2 PM [19] would be approx. 0.2 nM/s (4%/min). On the 
other hand, inside cells the high concentration of GSH 
may result in the rapid conversion of imported Snitroso- 
thiols to GSNO. For instance 0.3 PM cySN0 would be 
converted to GSNO by 5 mM GSH at an initial rate of 
0.13 /&i/s (43%/s). 
k2 values were obtained for the reaction of the major 
known human plasma protein S-nitrosothiol (i.e. 
albSN0) with cysteine (e.g. Fig. 2) and with GSH (Table 
1). The initial rate of SNO-SH exchange between human 
venous plasma levels of albSN0 (7 PM [9]) and cysteine 
(9.2pM [19]) would be 35 nM/min (0.5l%/min), and with 
GSH (4.6 PM [19]) would be 6 nM/min (O.O9%/min). 
_.... ,,... 
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Fig. 1. Kinetics of SNO-SH exchange between equimolar penSNO and 
GSH. (a) To 2.3 mM penSNO in buffer A in a polystyrene cuvette was 
added (at arrow) 2.3 mM GSH and the SNO-SH exchange reaction 
monitored at 600 nm. (b) k2 was determined from the slope of a plot 
of l/[penSNO] (or l/[GSI-Il) vs. time. K_, was determined from the 
equilibrium concentrations of thiols and S-nitrosothiols (method 1, see 
section 2.3.1.). 
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Fig. 2. Kinetics of SNGSH exchange between albSN0 and excess 
cysteine. (a) To 0.2 mM albSN0 in buffer A plus 20pM cupric sulphate 
in a polystyrene cuvette was added 3 mM cysteine. SNGSH exchange 
was determined from the reduction in A,, due to the very rapid copper- 
dependent decomposition of cySN0. (b) A pseudo-first order rate con- 
stant was obtained from a plot of log,,, [albSNO] vs. time, hence a value 
for k,. 
These rates are expected to be higher in arterial blood 
since the content of GSH and cysteine are higher, but are 
still remarkably low. 
One may conclude that, in the extracellular milieu, 
where low molecular weight thiol concentrations are low, 
SNCLSH exchange is unimportant and potential S-ni- 
troso-containing therapeutic agents should be relatively 
stable. Hence their physiological actions should be at- 
tributable directly to the applied agent. However, if the 
compounds were to enter or traverse cells (e.g. endothe- 
lium), conversion to GSNO is likely to be substantial and 
physiological effects are predicted to be due largely to 
GSNO. 
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